An overview of human proteins and genes involved in SARS-CoV-2 infection

[1]  L. Davis,et al.  Integrative genomic analyses identify susceptibility genes underlying COVID-19 hospitalization , 2021, Nature Communications.

[2]  Duo Liu,et al.  An integrative multiomics analysis identifies putative causal genes for COVID-19 severity , 2021, Genetics in Medicine.

[3]  K. Jöckel,et al.  Transmembrane serine protease 2 Polymorphisms and Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Type 2 Infection: A German Case-Control Study , 2021, Frontiers in Genetics.

[4]  G. Petrovski,et al.  An Update on COVID-19 Related Ophthalmic Manifestations , 2021, Ocular immunology and inflammation.

[5]  S. McSweeney,et al.  Structural basis for SARS-CoV-2 envelope protein recognition of human cell junction protein PALS1 , 2021, Nature Communications.

[6]  Heping Zhang,et al.  Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data , 2021, Human genomics.

[7]  C. Szeto,et al.  The presentation of SARS-CoV-2 peptides by the common HLA-A∗02:01 molecule , 2021, iScience.

[8]  A. Coppola,et al.  ACE Gene I/D Polymorphism and Acute Pulmonary Embolism in COVID19 Pneumonia: A Potential Predisposing Role , 2021, Frontiers in Medicine.

[9]  D. Tang,et al.  The BET family in immunity and disease , 2021, Signal Transduction and Targeted Therapy.

[10]  B. Taneri,et al.  Host Genetics at the Intersection of Autoimmunity and COVID-19: A Potential Key for Heterogeneous COVID-19 Severity , 2020, Frontiers in Immunology.

[11]  Y. Bi,et al.  ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated assembly of the SNARE complex required for autolysosome formation , 2020, Developmental Cell.

[12]  S. Pääbo,et al.  The MERS-CoV receptor gene is among COVID-19 risk factors inherited from Neandertals , 2020, bioRxiv.

[13]  Y. Hu,et al.  [Asymptomatic infection of COVID-19 and its challenge to epidemic prevention and control]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.

[14]  Jonathan P. Davies,et al.  Comparative Multiplexed Interactomics of SARS-CoV-2 and Homologous Coronavirus Nonstructural Proteins Identifies Unique and Shared Host-Cell Dependencies , 2020, ACS infectious diseases.

[15]  Huanming Yang,et al.  Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility , 2020, Cell discovery.

[16]  A. Kolocouris,et al.  Structure and drug binding of the SARS-CoV-2 envelope protein transmembrane domain in lipid bilayers , 2020, Nature Structural & Molecular Biology.

[17]  Miguel Correa Marrero,et al.  Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms , 2020, Science.

[18]  Y. Tomita,et al.  Association between HLA gene polymorphisms and mortality of COVID‐19: An in silico analysis , 2020, Immunity, inflammation and disease.

[19]  Barbara B. Shih,et al.  Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.

[20]  Jacques Fellay,et al.  Inborn errors of type I IFN immunity in patients with life-threatening COVID-19 , 2020, Science.

[21]  Y. Qiu,et al.  SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2 , 2020, Cell discovery.

[22]  V. Álvarez,et al.  Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome , 2020, Gene.

[23]  M. Helmer-Citterich,et al.  COVID-19 and Genetic Variants of Protein Involved in the SARS-CoV-2 Entry into the Host Cells , 2020, Genes.

[24]  M. A. Wemyss,et al.  The diverse roles of RIP kinases in host-pathogen interactions , 2020, Seminars in Cell & Developmental Biology.

[25]  Maohui Luo,et al.  Multi-organ proteomic landscape of COVID-19 autopsies , 2020, Cell.

[26]  J. Borghi,et al.  Epidemiology of COVID‐19: A systematic review and meta‐analysis of clinical characteristics, risk factors, and outcomes , 2020, Journal of medical virology.

[27]  Ze-Guang Han,et al.  SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70 , 2020, Cellular & Molecular Immunology.

[28]  R. Lal,et al.  Comparative Genomic Analysis of Rapidly Evolving SARS-CoV-2 Reveals Mosaic Pattern of Phylogeographical Distribution , 2020, mSystems.

[29]  J. Schuurs-Hoeijmakers,et al.  Presence of Genetic Variants Among Young Men With Severe COVID-19. , 2020, JAMA.

[30]  A. d’Arminio Monforte,et al.  ACE2 gene variants may underlie interindividual variability and susceptibility to COVID-19 in the Italian population , 2020, European Journal of Human Genetics.

[31]  M. Chung,et al.  New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis , 2020, BMC Medicine.

[32]  Sharon J Peacock,et al.  Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. , 2020, JAMA.

[33]  N. Ban,et al.  SARS-CoV-2 Nsp1 binds ribosomal mRNA channel to inhibit translation , 2020, bioRxiv.

[34]  Ramars Amanchy,et al.  Genetic variants in TMPRSS2 and Structure of SARS-CoV-2 spike glycoprotein and TMPRSS2 complex , 2020, bioRxiv.

[35]  G. Lippi,et al.  Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? , 2020, Clinical chemistry and laboratory medicine.

[36]  Andrew R. Leach,et al.  The Global Phosphorylation Landscape of SARS-CoV-2 Infection , 2020, Cell.

[37]  C. Nicholson,et al.  Polymorphisms in the ACE2 Locus Associate with Severity of COVID-19 Infection , 2020, medRxiv.

[38]  S. Brohawn,et al.  Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs , 2020, bioRxiv.

[39]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[40]  M. Ciulla.  SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs , 2020, Hypertension Research.

[41]  V. Markides,et al.  Angiotensin Converting Enzyme 2 May Mediate Disease Severity In COVID-19 , 2020, The American Journal of Cardiology.

[42]  Nehla Banu,et al.  Protective role of ACE2 and its downregulation in SARS-CoV-2 infection leading to Macrophage Activation Syndrome: Therapeutic implications , 2020, Life Sciences.

[43]  N. Krogan,et al.  The Landscape of Human Cancer Proteins Targeted by SARS-CoV-2 , 2020, Cancer discovery.

[44]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[45]  Leora I. Horwitz,et al.  Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.

[46]  W. Figg,et al.  TMPRSS2: Potential Biomarker for COVID‐19 Outcomes , 2020, Journal of clinical pharmacology.

[47]  Axel Haverich,et al.  Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. , 2020, The New England journal of medicine.

[48]  Weiqiang Lin,et al.  Investigation of the genetic variation in ACE2 on the structural recognition by the novel coronavirus (SARS-CoV-2) , 2020, Journal of Translational Medicine.

[49]  Ji He,et al.  Distribution of HLA allele frequencies in 82 Chinese individuals with coronavirus disease‐2019 (COVID‐19) , 2020, HLA.

[50]  Thomas Becker,et al.  Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2 , 2020, Science.

[51]  A. Hasan,et al.  The expression level of angiotensin-converting enzyme 2 determines the severity of COVID-19: lung and heart tissue as targets , 2020, Journal of biomolecular structure & dynamics.

[52]  V. Gasic,et al.  Functional prediction and comparative population analysis of variants in genes for proteases and innate immunity related to SARS-CoV-2 infection , 2020, bioRxiv.

[53]  J. Thachil,et al.  Coagulation abnormalities and thrombosis in patients with COVID-19 , 2020, The Lancet Haematology.

[54]  Animesh K. Singh,et al.  Global Spread of SARS-CoV-2 Subtype with Spike Protein Mutation D614G is Shaped by Human Genomic Variations that Regulate Expression of TMPRSS2 and MX1 Genes , 2020, bioRxiv.

[55]  G. Barton,et al.  Missense variants in ACE2 are predicted to encourage and inhibit interaction with SARS-CoV-2 Spike and contribute to genetic risk in COVID-19 , 2020, bioRxiv.

[56]  Benjamin J. Polacco,et al.  A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug-Repurposing , 2020, Nature.

[57]  A. Puca,et al.  COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children , 2020, Frontiers in Pediatrics.

[58]  A. Spanevello,et al.  The pivotal link between ACE2 deficiency and SARS-CoV-2 infection , 2020, European Journal of Internal Medicine.

[59]  Holger Moch,et al.  Endothelial cell infection and endotheliitis in COVID-19 , 2020, The Lancet.

[60]  Abhinav Nellore,et al.  Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2 , 2020, Journal of Virology.

[61]  Steven J. M. Jones,et al.  ACE 2 Coding Variants: A Potential X-linked Risk Factor for COVID-19 Disease , 2020, bioRxiv.

[62]  Frederic A. Fellouse,et al.  Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility , 2020, bioRxiv.

[63]  Mushtaq Hussain,et al.  Structural variations in human ACE2 may influence its binding with SARS‐CoV‐2 spike protein , 2020, Journal of medical virology.

[64]  E. Lakatta,et al.  The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights From Cardiovascular Aging Science. , 2020, JAMA cardiology.

[65]  Xiaoxu Tian,et al.  Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis , 2020, bioRxiv.

[66]  A. Mantovani,et al.  ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy , 2020, medRxiv.

[67]  Vineet D. Menachery,et al.  Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV , 2020, Journal of Virology.

[68]  G. Herrler,et al.  SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor , 2020, Cell.

[69]  Qiang Zhou,et al.  Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2 , 2020, Science.

[70]  Ruchong Chen,et al.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.

[71]  P. Niu,et al.  Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China , 2020, Cell Host & Microbe.

[72]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.

[73]  Gregory M. Cooper,et al.  CADD: predicting the deleteriousness of variants throughout the human genome , 2018, Nucleic Acids Res..

[74]  M. Duan,et al.  The induction and consequences of Influenza A virus-induced cell death , 2018, Cell Death & Disease.

[75]  Min Wang,et al.  SARS-Coronavirus Open Reading Frame-3a drives multimodal necrotic cell death , 2018, Cell Death & Disease.

[76]  A. Tesei,et al.  Sigma Receptors as Endoplasmic Reticulum Stress “Gatekeepers” and their Modulators as Emerging New Weapons in the Fight Against Cancer , 2018, Front. Pharmacol..

[77]  H. Karimian,et al.  Mitochondrial outer membrane permeabilization: a focus on the role of mitochondrial membrane structural organization , 2017, Biophysical Reviews.

[78]  김상욱,et al.  Predicting the functional impact of protein mutations using coevolutionary signals , 2016 .

[79]  Y. Shang,et al.  Role of Notch signaling in regulating innate immunity and inflammation in health and disease , 2016, Protein & Cell.

[80]  M. Obeidat,et al.  Identification of TMPRSS2 as a Susceptibility Gene for Severe 2009 Pandemic A(H1N1) Influenza and A(H7N9) Influenza , 2015, The Journal of infectious diseases.

[81]  I. Adzhubei,et al.  Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.

[82]  R. Bruzzone,et al.  The SARS coronavirus E protein interacts with the PALS1 and alters tight junction formation and epithelial morphogenesis , 2010, Molecular biology of the cell.

[83]  R. Bruzzone,et al.  The SARS Coronavirus E Protein Interacts with PALS1 and Alters Tight Junction Formation and Epithelial Morphogenesis , 2010, Molecular Biology of the Cell.

[84]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[85]  P. Woo,et al.  Phylogenetic and recombination analysis of coronavirus HKU1, a novel coronavirus from patients with pneumonia , 2005, Archives of Virology.

[86]  T. Greenough,et al.  What’s new in the renin-angiotensin system? , 2004, Cellular and Molecular Life Sciences CMLS.

[87]  E. Wood.  The Lancet Oncology , 2003 .

[88]  S. Henikoff,et al.  Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.

[89]  M. Buchmeier,et al.  Coronavirus Spike Proteins in Viral Entry and Pathogenesis , 2001, Virology.

[90]  J. Krolewski,et al.  Molecular characterization of an alpha interferon receptor 1 subunit (IFNaR1) domain required for TYK2 binding and signal transduction , 1996, Molecular and cellular biology.

[91]  Florey,et al.  The endothelial cell. , 1966, British medical journal.

[92]  M. Tadesse,et al.  Integrative genomic analyses , 2017 .

[93]  Christin Wirth,et al.  Biomolecular Structure And Dynamics , 2016 .

[94]  Matthias Cavassini,et al.  [Infectious diseases]. , 2014, Revue medicale suisse.

[95]  Gary D Bader,et al.  Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers , 2013 .

[96]  B. J. Montoya-Arce,et al.  Factors Associated , 2013 .

[97]  I. Nishio,et al.  [Angiotensin I converting enzyme]. , 1999, Nihon rinsho. Japanese journal of clinical medicine.